How many drugs treat Pneumococcal pneumonia?

Drug Landscape tracks 10 marketed treatments for Pneumococcal pneumonia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Pneumococcal pneumonia?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pneumococcal-pneumonia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pneumococcal pneumonia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pneumococcal pneumonia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumococcal pneumonia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Teflaro	CEFTAROLINE FOSAMIL	AbbVie	Cephalosporin Antibacterial		2010-01-01
Ketek	TELITHROMYCIN	Sanofi	Ketolide Antibacterial	Potassium voltage-gated channel subfamily H member 2	2004-01-01
Factive	GEMIFLOXACIN MESYLATE	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Factive	GEMIFLOXACIN	Lg Chem Ltd	Quinolone Antimicrobial		2003-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 4 drugs in Pneumococcal pneumonia
· 4 drugs in Pneumococcal pneumonia
Lg Chem Ltd · 2 drugs in Pneumococcal pneumonia
Baxter · 2 drugs in Pneumococcal pneumonia
Bayer AG · 1 drug in Pneumococcal pneumonia
Bristol-Myers Squibb · 1 drug in Pneumococcal pneumonia
Dr Reddys Labs Inc · 1 drug in Pneumococcal pneumonia
Generic (originally Abbott/AbbVie) · 1 drug in Pneumococcal pneumonia
Generic (originally Abbott/Lilly) · 1 drug in Pneumococcal pneumonia
Generic (originally Beecham/GSK) · 1 drug in Pneumococcal pneumonia
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Pneumococcal pneumonia
Generic (originally Upjohn/Pfizer) · 1 drug in Pneumococcal pneumonia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumococcal pneumonia:

Cite this brief

Drug Landscape (2026). Pneumococcal pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumococcal-pneumonia. Accessed 2026-06-10.

Pneumococcal pneumonia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing